Regeneron Immunotherapy Combo Comes up Short in Melanoma Trial

Regeneron immunotherapy combo comes up short in melanoma trial

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

Stocks making the biggest moves premarket: Regeneron, Dominion Energy, Macy's & more

These are the stocks posting the largest moves premarket.

Regeneron stock drops double digits on oncology trial failure

Regeneron stock drops double digits on oncology trial failure

Stocks making the biggest moves midday: Regeneron, Dominion, Mobileye, Viking and more

Subscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsSelect Personal FinanceJoin the CNBC PanelClosed CaptioningDigital ProductsNews ReleasesInternshipsCorrectionsAbout CNBCSite MapPodcastsCareersHelpContactNews TipsGot a confidential news tip? We want to hear from you.Get In TouchCNBC NewslettersSign up for free newsletters and get more CNBC delivered to your inboxSign Up NowGet this delivered to your inbox, and more…